Thanks to the various blogs (BrandWeekNrx, PharmaGossip, PharmaLot, PharmaBlogosphere, and others) that reported on this blog's inaugural posts. To clarify, the name of the blog is not "Ask Pharmie." Ask Pharmie is a feature that will appear from time t

FTC Commissioner Supports Bill Banning Reverse Payments PAL and 20 other organizations recently sent letters to the members of the House Energy and Commerce Committee, supporting HR 1092, the “Protecting Consumer Access to Generic Drugs Act of 2007." FDA

"Ask Pharmie" started as a feature in PAL's newsletter, which was printed approximately quarterly until the end of 2006. (Archive issues are here.) We've now shifted from a printed newsletter to this exclusively online publications (including this blog)

The New York Times ran a story on Wednesday about the pros and cons of doctors distributing prescription drug samples. The article cites the critique (with which we here at PAL are in agreement) that samples are a form of marketing, intended to get physi

Two new stories that came out today call the question of what effect US Attorney settlements have on illegal promotional activities by pharmaceutical companies. The first story, from AP, "Drug Firms Flout FDA," suggested that "Even when drug makers are

This blog will feature updates on activities of Prescription Access Litigation (PAL) and its members, including class action lawsuits, amicus curiae (Friend of the Court") briefs, regulatory and legislative testimony and public education campaigns. We wil

Today, the Centers for Medicare and Medicaid Services (CMS) approved a proposal from Utah that imposes harmful and unprecedented restrictions on the Medicaid expansion program that Utah voters approved last November.